Primary cutaneous large-cell lymphoma: analysis of 49 patients included in the LNH87 prospective trial of polychemotherapy for high-grade lymphomas
Primary cutaneous large-cell lymphoma: analysis of 49 patients included in the LNH87 prospective trial of polychemotherapy for high-grade lymphomas
复制标题
原发性皮肤大细胞淋巴瘤：对 LNH87 联合化疗治疗高级别淋巴瘤前瞻性试验中纳入的 49 名患者进行分析
DOI：
10.1038/sj.leu.2400911
复制
发表时间：
1998
期刊：
影响因子：
11.4
通讯作者：
for the Groupe d’Etude des Lymphomes de l’Adulte
中科院分区：
文献类型：
--
作者：
P. Brice;D. Cazals;N. Mounier;O. Vérola;AM Neidhart;L. Réménieras;E. Deconinck;C. Doyen;J. Hamelsand;T. Molina;I. Moulonguet;C. Gisselbrecht;for the Groupe d’Etude des Lymphomes de l’Adulte
本研究的目的是评估原发性皮肤大细胞淋巴瘤（PCLL）患者联合化疗后的结果，并验证最近提出的皮肤淋巴瘤免疫组织学分类。在 LNH87 方案（用于治疗侵袭性淋巴瘤）中，140 名皮肤活检呈阳性的患者中，49 名患者符合 PCLL 标准。特征为：男/女性别比，2.3；年龄 18 至 83 岁（中位数 52），周围淋巴结，n = 22；弥漫性疾病，n = 12；肿瘤大小中位数，4.5cm；乳酸脱氢酶升高，n = 9； ECOG：0/1，n = 49。组织学为：滤泡中心B细胞，n = 23； B-淋巴母细胞，n = 1；间变性大细胞淋巴瘤，n = 14（T细胞表型n = 8）； CD30− T 细胞淋巴瘤，n = 11。所有患者均接受联合化疗：70 岁以下，ACVBP（3 至 4 个周期，巩固 6 个月）n = 25； mBACOD（八个周期）n = 16；超过 70 年，C(T)VP（六个周期）n = 8。方案中不包括放射治疗。中位随访 5 年，24/49 例患者复发，其中 20 例皮肤复发。 5 年无事件生存率 (EFS) 和总生存率 (OS) 分别为 50% 和 77%。显着的不良预后因素是：组织学（CD30−T细胞淋巴瘤）和弥漫性皮肤病（> 10%的皮肤）。淋巴结受累的存在仅对 EFS 有意义。与同一试验中纳入且主要临床特征完全匹配的 140 名非皮肤淋巴瘤患者相比，OS 相似。总之，PCLL 与其他局限性 B 或 T 细胞结外淋巴瘤具有相同的预后因素（LDH、ECOG、年龄），但 CD30+ PCLL 具有非常好的预后。
The objectives of this study were to evaluate the outcome after polychemotherapy for patients with primary cutaneous large-cell lymphomas (PCLL) and to validate the recently proposed immunohistologic classification of cutaneous lymphomas. Among 140 patients with positive skin biopsies included in the LNH87 protocol (for treatment of aggressive lymphomas), 49 patients met the criteria of PCLL. Characteristics were: sex ratio M/F, 2.3; age 18 to 83 years (median, 52), peripheral lymph nodes, n = 22; diffuse disease, n = 12; median tumor size, 4.5 cm; elevated lactate dehydrogenase, n = 9; ECOG: 0/1, n = 49. Histology was: follicular center B cell, n = 23; B-lymphoblastic, n = 1; anaplastic large-cell lymphoma, n = 14 (T cell phenotype n = 8); CD30− T cell lymphoma, n = 11. All patients received polychemotherapy: under 70 years, ACVBP (three to four cycles and consolidation for 6 months) n = 25; mBACOD (eight cycles) n = 16; over 70 years, C(T)VP (six cycles) n = 8. Radiation therapy was not included in the protocol. With a median follow-up of 5 years, 24/49 patients had relapsed, with 20 skin relapses. Event-free (EFS) and overall survival (OS) at 5 years were, respectively, 50 and 77%. Significant adverse prognostic factors were: histology (CD30− T cell lymphoma) and diffuse cutaneous disease (>10% of skin). The presence of nodal involvement was only significant for EFS. When compared to 140 non-cutaneous lymphoma patients included in the same trial and fully matched for the main clinical characteristics, OS was similar. In conclusion, PCLL behaves like other localized B or T cell extranodal lymphomas with the same prognostic factors (LDH, ECOG, age) except for CD30+ PCLL which have a very good prognosis.
除蕈样肉芽肿之外的皮肤淋巴瘤的免疫学和临床病理学异质性。
影响因子：
20.3
作者：
Wood,GS;Burke,JS;Horning,S;Doggett,RS;Levy,R;Warnke,RA
通讯作者：
Warnke,RA
影响因子：
158.5
作者：
FISHER, RI;GAYNOR, ER;MILLER, TP
通讯作者：
MILLER, TP